Ge Long Hui A P P·2025-08-25 06:25Core Viewpoint - The report from China Merchants Securities International indicates that China's biopharmaceutical sector experienced a 10% year-on-year revenue increase in the first half, reaching 17.6 billion yuan, exceeding expectations [1] Group 1: Company Performance - The management guidance suggests an acceleration in growth for the second half of the year, with projections indicating a return to double-digit growth in 2026 and 2027 [1] - The growth potential in the respiratory and liver disease sectors is considered underestimated by the market, as the company possesses superior growth prospects and abundant business development opportunities [1] Group 2: Market Position and Strategy - The firm maintains an optimistic outlook on China National Pharmaceutical Group, viewing it as a market leader benefiting from strong performance in oncology, surgical, and analgesic drugs [1] - The impact of centralized procurement policies on average prices is expected to stabilize, reducing negative effects [1] - The company has effectively refocused on four major therapeutic areas through asset disposals, which is anticipated to enhance overall operational efficiency and quality [1] Group 3: Target Price and Rating - The target price for the company has been raised to 9.8 Hong Kong dollars, with a maintained "Buy" rating [1]